{
    "clinical_study": {
        "@rank": "55303", 
        "arm_group": [
            {
                "arm_group_label": "R-CHOP", 
                "arm_group_type": "Active Comparator", 
                "description": "6 cycles every 21 days.\nRituximab: intravenous, 375 mg/m2, day 1\nCyclophosphamide: intravenous, 750 mg/m2, day 1\nDoxorubicin: intravenous,  50 mg/m2, day 1\nVincristine: intravenous, 1,4 mg/m2, day 1\nPrednisone: oral, 100 mg, days 1-5"
            }, 
            {
                "arm_group_label": "B-R-CAP", 
                "arm_group_type": "Experimental", 
                "description": "6 cycles every 21 days\nBortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15\nRituximab: intravenous, 375 mg/m2, day 1\nCyclophosphamide: intravenous, 750 mg/m2, day 1\nDoxorubicin: intravenous,  50 mg/m2, day 1\nPrednisone: oral, 100 mg, days 1-5"
            }
        ], 
        "brief_summary": {
            "textblock": "Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, accounting\n      for between 30% and 50% of the patients. Although it is considered a curable disease, still\n      at least 40 % of the patients will fail first line chemotherapy. The International\n      Prognostic Index (IPI) score and the age adjusted IPI (aIPI) has been used since they were\n      published to identify patients with different outcome.\n\n      There is not standard therapy for young patients with DLBCL and unfavourable IPI score. The\n      survival of these patients remains poor, with EFS around 40%.\n\n      The combination of RCHOP with new drugs is an attractive approach to treat these patients.\n\n      The goal is to evaluate the proportion of patients with Event-Free Survival (EFS) after 2\n      years, with a diagnosis of  DLBCL with an aIPI > 1 or an aIPI =1 with increased levels of\n      beta-2-microglobulin (above the Upper Limits of Normal.)"
        }, 
        "brief_title": "Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Diffuse, Large B-Cell, Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "detailed_description": {
            "textblock": "Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, accounting\n      for between 30% and 50% of the patients. Although it is considered a curable disease, still\n      at least 40 % of the patients will fail first line chemotherapy. The International\n      Prognostic Index (IPI) score and the age adjusted IPI (aIPI) has been used since they were\n      published to identify patients with different outcome.\n\n      CHOP chemotherapy administered every 21 days has been for years the standard therapy for\n      advanced DLBCL achieving a long term overall survival (OS) of about 40%. Many studies show\n      that the addition of the monoclonal antibody Rituximab improves the patients survival\n      achieving higher rates of event-free survival in elderly patients with both,favourable and\n      unfavourable IPI score. R-CHOP also improved survival in young patients with favourable IPI\n      score.\n\n      There is not standard therapy for young patients with DLBCL and unfavourable IPI score. The\n      survival of these patients remains poor, with EFS around 40%.\n\n      The combination of RCHOP with new drugs is an attractive approach to treat these patients.\n\n      The investigators propose a phase II randomized clinical trial for young patients with\n      unfavourable IPI score DLBCL using 6 cycles of the combination of subcutaneous Bortezomib\n      with R-CAP (RCHOP without vincristine, to avoid neuropathy) comparing with the standard\n      immunochemotherapy regimen R- CHOP every 21 days.\n\n      The goal is to evaluate the proportion of patients with Event-Free Survival (EFS) after 2\n      years, with a diagnosis of DLBCL with aIPI > 1 or aIPI =1 with increased levels of\n      beta-2-microglobulin (above the Upper Limits of Normal)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients diagnosed with primary diffuse DLBCL  who have never received     treatment\n             for this condition.\n\n          -  Age between 18 and 70 years.\n\n          -  Age-adjusted IPI (aIPI) higher than 1, or equal 1 with high levels of\n             beta-2-microglobulin (above UNL)\n\n          -  Cluster of Differentiation 20 (CD20) positive b lymphocytes.\n\n          -  Eastern Cooperative Oncology Group (ECOG) 0-3.\n\n          -  More than 12 weeks of life expectancy.\n\n          -  Signed Informed Consent.\n\n          -  Nor pregnant women nor breast-feeding women without heterosexual activity during the\n             entire study. Women with heterosexual activity only if they are willing to use two\n             methods of contraceptive. The two contraceptive methods can be, two barrier method or\n             a barrier method combinated with an hormonal contraceptive method to prevent\n             pregnancy, used during the entire study and until 3 months after the study\n             completion.\n\n        Exclusion Criteria:\n\n          -  Pregnant women or in breast-feeding period, or adults in childbearing period not\n             using an effective contraception method.\n\n          -  Patients with Central Nervous System (CNS) lymphoma.\n\n          -  Severely impaired renal function (creatinine> 2.5 UNL) or hepatic function impairment\n             (bilirubin or Alanine Amino Transaminase (ALT) / Aspartate Aminotransferase (AST) > 3\n             UNL), unless it is suspected to be due to the disease.\n\n          -  Hepatitis B virus (HIV) positive patients\n\n          -  Patient previously treated for the DLBCL\n\n          -  Positive determination of chronic hepatitis B (defined as positive serology for\n             HBsAg). It will be allowed to enroll patients with hidden or previous hepatitis B\n             (defined as positive antibodies against the core of the hepatitis B virus [HBcAb] and\n             HBsAg negative) if undetectable Hepatitis B Virus (HBV) DNA.\n\n          -  Positive results for hepatitis C (antibody serology for hepatitis C virus ((HCV)).\n             Patients with HCV positive may only participate if the Polymerase Chain Reaction\n             (PCR) result is negative for HCV RNA.\n\n          -  History of cardiovascular disease with ventricular ejection fraction < 50%.\n\n          -  Patients with severe psychiatric conditions that may interfere with their ability to\n             understand the study (including alcoholism or drug addiction).\n\n          -  Patients with known hypersensitivity to murine proteins or any other components of\n             the study drugs.\n\n          -  Transformed follicular lymphoma.\n\n          -  History of other neoplastic malignancy with < 5 year of complete response (except for\n             Squamous Cell Carcinoma of the Skin or cervical Carcinoma in situ).\n\n          -  Presence of uncontrolled conditions: cardiac, respiratory, neurologic, metabolic\n             etc., not related to lymphoma.\n\n          -  Uncontrolled hypertension (diastolic blood pressure over 110 mmHg)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "127", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01848132", 
            "org_study_id": "BRCAP-GELTAMO12", 
            "secondary_id": "2012-005138-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "B-R-CAP", 
                "description": "Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15.", 
                "intervention_name": "Bortezomib", 
                "intervention_type": "Drug", 
                "other_name": "Velcade"
            }, 
            {
                "arm_group_label": [
                    "R-CHOP", 
                    "B-R-CAP"
                ], 
                "description": "Rituximab: intravenous, 375 mg/m2, day 1", 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug", 
                "other_name": "Rituximab"
            }, 
            {
                "arm_group_label": [
                    "R-CHOP", 
                    "B-R-CAP"
                ], 
                "description": "Cyclophosphamide: intravenous, 750 mg/m2, day 1", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "Cyclophosphamide"
            }, 
            {
                "arm_group_label": [
                    "R-CHOP", 
                    "B-R-CAP"
                ], 
                "description": "Adriamycin:intravenous,  50 mg/m2, day 1", 
                "intervention_name": "Doxorubicin", 
                "intervention_type": "Drug", 
                "other_name": "Adriamycin"
            }, 
            {
                "arm_group_label": [
                    "R-CHOP", 
                    "B-R-CAP"
                ], 
                "description": "Prednisone: oral, 100 mg, days 1-5", 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug", 
                "other_name": "Prednisone"
            }, 
            {
                "arm_group_label": "R-CHOP", 
                "description": "Vincristine: intravenous, 1,4 mg/m2, day 1", 
                "intervention_name": "Vincristine", 
                "intervention_type": "Drug", 
                "other_name": "Vincristine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Rituximab", 
                "Bortezomib", 
                "Doxorubicin", 
                "Prednisone", 
                "Vincristine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lymphoma", 
            "Large B-Cell"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "contact": {
                    "email": "lpalomera@salud.aragon.es", 
                    "last_name": "Luis Ram\u00f3n Palomera, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain", 
                        "state": "Arag\u00f3n", 
                        "zip": "50009"
                    }, 
                    "name": "Hospital Cl\u00ednico Universitario Lozano Blesa"
                }, 
                "investigator": {
                    "last_name": "Luis Ram\u00f3n Palomera, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oviedo", 
                        "country": "Spain", 
                        "state": "Asturias", 
                        "zip": "33006"
                    }, 
                    "name": "Hospital Universitario Central de Asturias"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Badalona", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08916"
                    }, 
                    "name": "Institut Catal\u00e0 d'Oncologia, Hospital Germans Trias i Pujol"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "e.gonzalez@iconcologia.net", 
                    "last_name": "Eva Gonz\u00e1lez, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Hospitalet de Llobregat", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08908"
                    }, 
                    "name": "Institut Catal\u00e0 d'Oncologia, Hospital Duran i Reynals"
                }, 
                "investigator": {
                    "last_name": "Eva Gonz\u00e1lez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santander", 
                        "country": "Spain", 
                        "state": "Cantabria", 
                        "zip": "39008"
                    }, 
                    "name": "Hospital Universitario Marqu\u00e9s de Valdecilla"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jerez de la Frontera", 
                        "country": "Spain", 
                        "state": "C\u00e1diz", 
                        "zip": "11407"
                    }, 
                    "name": "Hospital de Jerez"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca", 
                        "country": "Spain", 
                        "state": "Islas Baleares", 
                        "zip": "07198"
                    }, 
                    "name": "Hospital Son Ll\u00e0tzer"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alcorc\u00f3n", 
                        "country": "Spain", 
                        "state": "Madrid", 
                        "zip": "28922"
                    }, 
                    "name": "Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "cpanizo@unav.es", 
                    "last_name": "Carlos Panizo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Pamplona", 
                        "country": "Spain", 
                        "state": "Navarra", 
                        "zip": "31008"
                    }, 
                    "name": "Cl\u00ednica Universidad de Navarra"
                }, 
                "investigator": {
                    "last_name": "Carlos Panizo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "andlopez@vhebron.net", 
                    "last_name": "Andr\u00e9s L\u00f3pez, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Hospital Universitari Vall d'Hebron"
                }, 
                "investigator": {
                    "last_name": "Andr\u00e9s L\u00f3pez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "alopezg@clinic.ub.es", 
                    "last_name": "Armando L\u00f3pez, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "Hospital Clinic i Provincial de Barcelona"
                }, 
                "investigator": {
                    "last_name": "Armando L\u00f3pez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cgrande.hdoc@salud.madrid.org", 
                    "last_name": "Carlos Grande, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital Universitario 12 de Octubre"
                }, 
                "investigator": {
                    "last_name": "Carlos Grande, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Mcanales.hulp@salud.madrid.org", 
                    "last_name": "Miguel \u00c1ngel Canales, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28046"
                    }, 
                    "name": "Hospital Universitario La Paz"
                }, 
                "investigator": {
                    "last_name": "Miguel \u00c1ngel Canales, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28031"
                    }, 
                    "name": "Hospital Universitario Infanta Leonor"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "jperezoteyza@hmhospitales.com", 
                    "last_name": "Jaime P\u00e9rez de Oteyza, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "Centro Integral Oncol\u00f3gico Clara Campal"
                }, 
                "investigator": {
                    "last_name": "Jaime P\u00e9rez de Oteyza, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Hospital Universitario Ram\u00f3n y Cajal"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "amartingar@usal.es", 
                    "last_name": "Alejandro Mart\u00edn, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Salamanca", 
                        "country": "Spain", 
                        "zip": "37007"
                    }, 
                    "name": "Hospital Universitario de Salamanca"
                }, 
                "investigator": {
                    "last_name": "Alejandro Mart\u00edn, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "estrellacarrillocruz@gmail.com", 
                    "last_name": "Estrella Carrillo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41013"
                    }, 
                    "name": "Hospital Universitario Virgen del Roc\u00edo"
                }, 
                "investigator": {
                    "last_name": "Estrella Carrillo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46026"
                    }, 
                    "name": "Hospital Universitari i Polit\u00e8cnic La Fe"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "ferrer_sec@gva.es", 
                    "last_name": "Secundino Ferrer, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46017"
                    }, 
                    "name": "Hospital Universitario Doctor Peset"
                }, 
                "investigator": {
                    "last_name": "Secundino Ferrer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter Randomized Phase II Study of Treatment With R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.", 
        "other_outcome": {
            "description": "To explore the mutational profile in a selection of these cases by massive sequencing.\nTo analyze the impact of the molecular classification of DLBCL based on immunohistochemistry (IHC) (as Hans algorithms, Choi and Meyer) in the prospective series of the patients of this clinical trial.\nTo explore the effect of the expression of genes, Micro-Ribonucleic Acid (miRNAs) and proteins of interest. Refine the IHC analysis with automatic quantification methods of protein expression.\nTo explore the effect of frequent cytogenetic alterations in DLBCL.", 
            "measure": "Biological project", 
            "safety_issue": "No", 
            "time_frame": "During recruitment period, after patient randomization."
        }, 
        "overall_contact": {
            "email": "e.gonzalez@iconcologia.net", 
            "last_name": "Eva Gonzalez, MD", 
            "phone": "+34-93-2607750"
        }, 
        "overall_contact_backup": {
            "email": "geltamo@humv.es", 
            "last_name": "Ana Mar\u00eda M\u00e9ndez", 
            "phone": "+34 942 203450"
        }, 
        "overall_official": {
            "affiliation": "Institut Catal\u00e1 d'Oncolog\u00eda, Hospital Duran i Reynals", 
            "last_name": "Eva Gonz\u00e1lez, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Spanish Agency of Medicines", 
                "Spain: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the proportion of patients with event-free survival at 2 years in patients diagnosed of DLBCL with aIPI > 1 or aIPI=1 with elevated levels of beta 2-microglobulin (above UNL).\nUNL= Upper Normal Limit.", 
            "measure": "Proportion of patients with Event-Free Survival at 2 years.", 
            "safety_issue": "No", 
            "time_frame": "During treatment period, there will be assessments every 2 cycles. After end of treatment every 3 month the first year, every 6 months the second year and annually from 3rd to 5th year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01848132"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Event-free survival at 2 years in the different  subtypes of DLBCL subgroups: Germinal center B-cell-like (GCB)/non-GCB.", 
                "measure": "Event-Free survival at 2 years in the different subtypes of DLBCL", 
                "safety_issue": "No", 
                "time_frame": "Once the treatment is started, there will be weekly safety visits, visits before each treatment cycle, at day 60 after the sixth cycle and then follow-up visits every three months during the first 2 years and every 6 months until the 5th year"
            }, 
            {
                "description": "Overall survival at 2 years in patients diagnosed of DLBCL with aIPI > 1 or aIPI=1 with elevated levels of beta 2-microglobulin (above UNL)", 
                "measure": "Overall survival at 2 years", 
                "safety_issue": "No", 
                "time_frame": "Once the treatment is started, there will be weekly safety visits, visits before each treatment cycle, at day 60 after the sixth cycle and then follow-up visits every three months during the first 2 years and every 6 months until the 5th year."
            }, 
            {
                "description": "Overall response rate and complete remissions in patients diagnosed of DLBCL with aIPI > 1 or aIPI=1 with elevated levels of beta 2-microglobulin (above UNL).", 
                "measure": "Overall response rate and complete remissions", 
                "safety_issue": "No", 
                "time_frame": "Once the treatment is started, there will be weekly safety visits, visits before each treatment cycle, at day 60 after the sixth cycle and then follow-up visits every three months during the first 2 years and every 6 months until the 5th year."
            }, 
            {
                "description": "Toxicity according to the Common Toxicity Criteria (CTC) (version 3.0) of the National Cancer Institute (NCI).", 
                "measure": "Toxicity according to the CTC criteria", 
                "safety_issue": "Yes", 
                "time_frame": "Once the treatment is started, there will be weekly safety visits, visits before each treatment cycle, at day 60 after the sixth cycle and then follow-up visits every three months during the first 2 years and every 6 months until the 5th year."
            }, 
            {
                "description": "To evaluate the predictive value for EFS of interim PET/CT evaluation after 2 and 4 cycles of chemotherapy.\nThe PET Network group of Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea (GELTAMO), will conduct this blind  central review in real-time (qualitative and quantitative, prospective central review of the PET scans performed)", 
                "measure": "To evaluate the predictive value for EFS of interim PET/CT evaluation", 
                "safety_issue": "No", 
                "time_frame": "Before treatment, after second cycle, after fourth cycle and after treatment completion."
            }, 
            {
                "description": "To identify clinical and biological prognostic factors for response and survival.", 
                "measure": "To identify clinical and biological prognostic factors for response and survival.", 
                "safety_issue": "No", 
                "time_frame": "Once the treatment is started, there will be weekly safety visits, a visit before each treatment cycle, a visit at day 60 after the sixth cycle and then follow-up visits every three months the first 2 years and every 6 months until the 5th year."
            }
        ], 
        "source": "Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen-Cilag, S.A.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}